BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 14645434)

  • 1. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report.
    Bruera E; Driver L; Barnes EA; Willey J; Shen L; Palmer JL; Escalante C
    J Clin Oncol; 2003 Dec; 21(23):4439-43. PubMed ID: 14645434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial.
    Bruera E; Valero V; Driver L; Shen L; Willey J; Zhang T; Palmer JL
    J Clin Oncol; 2006 May; 24(13):2073-8. PubMed ID: 16648508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.
    Butler JM; Case LD; Atkins J; Frizzell B; Sanders G; Griffin P; Lesser G; McMullen K; McQuellon R; Naughton M; Rapp S; Stieber V; Shaw EG
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1496-501. PubMed ID: 17869448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
    Lower EE; Fleishman S; Cooper A; Zeldis J; Faleck H; Yu Z; Manning D
    J Pain Symptom Manage; 2009 Nov; 38(5):650-62. PubMed ID: 19896571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial.
    Kerr CW; Drake J; Milch RA; Brazeau DA; Skretny JA; Brazeau GA; Donnelly JP
    J Pain Symptom Manage; 2012 Jan; 43(1):68-77. PubMed ID: 22208450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
    Mendonça DA; Menezes K; Jog MS
    Mov Disord; 2007 Oct; 22(14):2070-6. PubMed ID: 17674415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does methylphenidate reduce the symptoms of chronic fatigue syndrome?
    Blockmans D; Persoons P; Van Houdenhove B; Bobbaers H
    Am J Med; 2006 Feb; 119(2):167.e23-30. PubMed ID: 16443425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modafinil for the treatment of fatigue in lung cancer: a pilot study.
    Spathis A; Dhillan R; Booden D; Forbes K; Vrotsou K; Fife K
    Palliat Med; 2009 Jun; 23(4):325-31. PubMed ID: 19270033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial.
    Bruera E; El Osta B; Valero V; Driver LC; Pei BL; Shen L; Poulter VA; Palmer JL
    J Clin Oncol; 2007 Aug; 25(23):3475-81. PubMed ID: 17687152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.
    Bruera E; Yennurajalingam S; Palmer JL; Perez-Cruz PE; Frisbee-Hume S; Allo JA; Williams JL; Cohen MZ
    J Clin Oncol; 2013 Jul; 31(19):2421-7. PubMed ID: 23690414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study.
    Strasser F; Palmer JL; Schover LR; Yusuf SW; Pisters K; Vassilopoulou-Sellin R; DeGracia B; Willey JS; Bruera E
    Cancer; 2006 Dec; 107(12):2949-57. PubMed ID: 17103445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer.
    Auret KA; Schug SA; Bremner AP; Bulsara M
    J Pain Symptom Manage; 2009 Apr; 37(4):613-21. PubMed ID: 18790598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study.
    Gagnon B; Low G; Schreier G
    J Psychiatry Neurosci; 2005 Mar; 30(2):100-7. PubMed ID: 15798785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with response to methylphenidate in advanced cancer patients.
    Yennurajalingam S; Palmer JL; Chacko R; Bruera E
    Oncologist; 2011; 16(2):246-53. PubMed ID: 21282671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of methylphenidate for the management of fatigue in Chinese patients with cancer.
    Siu SW; Law M; Liu RK; Wong KH; Soong IS; Kwok AO; Ng KH; Lam PT; Leung TW
    Am J Hosp Palliat Care; 2014 May; 31(3):281-6. PubMed ID: 23650644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study.
    Sarhill N; Walsh D; Nelson KA; Homsi J; LeGrand S; Davis MP
    Am J Hosp Palliat Care; 2001; 18(3):187-92. PubMed ID: 11406895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.